Feature | April 02, 2009

McKesson Releases Molecular Diagnostics Criteria Upgrade

April 2, 2009 - McKesson’s releases its 2009 InterQual Criteria and CareEnhance Review Manager 8.0 software features industry-leading innovations including molecular and genetic diagnostics criteria.

The new criteria, combined with the option for clients to access it via McKesson’s recently launched auto authorization capability, is designed to increase the value of the content for users while helping improve quality of care for patients.

“As we bring the latest versions of our criteria and software to market, we are focused on driving efficiencies for payors and providers while expanding into new content areas,” said Tammie Phillips, vice president of InterQual for McKesson Health Solutions. “Even as we address major industry issues with our new auto authorization functionality and molecular diagnostics content, we continue to enhance and add value to the existing elements of our solution suite that have made it the gold standard in evidence-based clinical decision support.”

McKesson’s auto authorization is a hosted, Web-based offering that leverages McKesson’s new Advanced Diagnostics Management solution. The offering automates the entire authorization process, from the initial request all the way through final authorization. McKesson’s auto authorization capability can incorporate InterQual Molecular Diagnostics Criteria and select Imaging Criteria—and soon selected Procedures Criteria—so that medical appropriateness is determined automatically for most requests. The content plus technology drive reduced administrative costs, better payor-provider relations and support optimal care.

The new InterQual Molecular Diagnostics Criteria is an important innovation included in this release. McKesson provides a comprehensive set of criteria to support decision-making for molecular diagnostic tests.

Molecular Diagnostics Criteria is updated quarterly so it is always current. To help healthcare organizations determine test appropriateness based on clinical evidence, InterQual Molecular Diagnostics Criteria covers over 225 tests that comprise approximately 85 percent of the costs in this growing area. A new question and answer format leads to service recommendations that include alternative and concurrent tests, allowing users to easily conduct reviews and act on information. In addition, pop-up notes and clinical evidence summaries drive evidence-based medicine to the point of decision-making with more efficiency. The content is available in CareEnhance Review Manager software as well as McKesson’s Advanced Diagnostics Management solution auto authorization capability.

For more information: www.mckesson.com

Related Content

Nuclear Cardiology Optimistic About Return to Pre-COVID-19 Exam Levels. An American Society of Nuclear Cardiology (ASNC) member survey are confident nuclear cardiology volumes will return to pre-pandemic levels. #COVID19 #SARScov2
News | Nuclear Imaging | June 01, 2020
June 1, 2020 — While acknowledging the challenges their specialty is facing, more than two-thirds of respondents to a
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Potassium Molybdate Mo 99 Source Vessels for RadioGenix System

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | February 18, 2020
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...